This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly's Coronavirus Antibody Shows Positive Effect in Phase II
by Zacks Equity Research
Lilly (LLY) is developing two coronavirus neutralizing antibody candidates as potential treatment for hospitalized COVID-19 patients. Treatment with one antibody candidate reduces hospitalization rate.
Gilead's Oncology Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
Gilead's (GILD) magrolimab obtains Breakthrough Therapy designation in the United States for the treatment of newly-diagnosed myelodysplastic syndrome (MDS).
M&A ETFs Sizzling on Recent Deal Activities
by Sweta Killa
After tumbling to the lowest level in more than a decade in the second quarter, global M&A activity gathered steam in September following the flurry of latest deal activities.
Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $66.20, moving -0.21% from the previous trading session.
Regeneron's Cocktail for Coronavirus Selected for RECOVERY Study
by Zacks Equity Research
Regeneron's (REGN) investigational anti-viral antibody cocktail, REGN-COV2, has been selected for evaluation in the RECOVERY study.
Biotech ETFs Soars on Gilead-Immunomedics Deal
by Sweta Killa
The acquisition will expand Gilead's portfolio of treatments for various types of cancer.
Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug
by Zacks Equity Research
Merck (MRK) buys rights to co-develop/co-commercialize Seattle Genetics' ladiratuzumab vedotin. It acquires exclusive license to commercialize Tukysa for HER2-positive cancers in Asia, the Middle East and Latin America
Stock Market News for Sep 15, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Monday reversing some of the losses of the last week.
ETFs in Focus on Tug of War Between Bulls and Bears
by Sweta Killa
Both bull and bear ETFs are showing immense potential as abrupt changes in sentiments have raised the appeal for these products.
M&A Activities Intensify in Pharma Industry
by Zacks Equity Research
M&A Activities Intensify in Pharma Industry.
No Econ Data, but Big Biopharma News
by Mark Vickery
Merck, Gilead and Lilly make progress on an otherwise slow news day.
Gilead to Buy Oncology Company Immunomedics for $21 Billion
by Zacks Equity Research
Gilead (GILD) looks to fortify its oncology portfolio with the acquisition of Immunomedics and the addition of Trodelvy to its portfolio.
Immunomedics to be Acquired by Gilead for About 21 Billion
by Zacks Equity Research
Immunomedics Inc. (IMMU) will be acquired by Gilead (GILD) for about $21 billion.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $64.51 in the latest trading session, marking a +0.58% move from the prior day.
Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
The Zacks Analyst Blog Highlights: Moderna, Sanofi, GSK, GILD and AMGN
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Sanofi, GSK, GILD and AMGN
Roche Gets FDA Nod for Gavreto for RET Fusion-Positive NSCLC
by Zacks Equity Research
Roche's (RHHBY) lung cancer arm gets a boost with the FDA approval of Gavreto for NSCLC.
Gilead Submits sBLA to FDA for CAR-T in Non-Hodgkin Lymphomas
by Zacks Equity Research
Gilead submits a supplemental Biologics License Application to the FDA for Yescarta for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.
Gilead-HiFiBiO Ink Deal to Develop Antibodies Against Leukemia
by Zacks Equity Research
Gilead's (GILD) subsidiary, Kite, enters into a two-year research deal with HiFiBiOto develop antibodies against acute myeloid leukemia.
Vaccine Hopes Rise Again: 4 Stocks to Watch
by Ritujay Ghosh
The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and Sanofi (SNY).
Gilead Sciences (GILD) Stock Moves -1.32%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $65.91, marking a -1.32% move from the previous day.
Sanofi, Glaxo Start Clinical Study on Coronavirus Vaccine
by Zacks Equity Research
Sanofi (SNY) and Glaxo have a collaboration to develop an adjuvant vaccine against coronavirus.
Gilead Inks Deal With Jounce to License an Oncology Candidate
by Zacks Equity Research
Gilead (GILD) signs a deal with Jounce Therapeutics to exclusively license the latter's monoclonal antibody, JTX-1811.
Sanofi's Kevzara Fails as a Potential COVID-19 Treatment
by Zacks Equity Research
Sanofi's (SNY) phase III study evaluating Kevzara in severely or critically ill patients hospitalized with COVID-19 fails to meet primary endpoint and key secondary endpoint.